South Africa Diabetes Drugs Market By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others); By Diabetes Types (Type 1, Type 2, Diabetes Type 3, Diabetes Type 4, Diabetes Type 5); By Route of Administration (Oral, Subcutaneous, Intravenous, Route of Administration 4, Route of Administration 5); By Technology (Technology 1, Technology 2, Technology 3); By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Distribution Channel 4, Distribution Channel 5); Regional Analysis – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Price: $2699
Published: | Report ID: 85143 | Report Format : Excel, PDF
South Africa Diabetes Drugs Market size was valued at USD 330.45 million in 2023 and is anticipated to reach USD 353.64 million by 2032, at a CAGR of 0.31% during the forecast period (2023-2032).
The South Africa diabetes drugs market is driven by the rising prevalence of diabetes, an aging population, and increasing urbanization, which contribute to lifestyle-related risk factors such as obesity and sedentary behavior. Government initiatives to improve healthcare access and the expansion of national health insurance programs support market growth. Advancements in diabetes treatment, including the adoption of innovative drugs like GLP-1 receptor agonists and SGLT2 inhibitors, enhance patient outcomes and drive demand. However, economic constraints and affordability issues limit access to advanced therapies. The increasing penetration of generic drugs, coupled with collaborations between pharmaceutical companies and healthcare providers, improves affordability and availability. Digital health solutions, including remote patient monitoring and telemedicine, are also gaining traction, enhancing diabetes management. Additionally, growing awareness campaigns and educational programs promote early diagnosis and treatment adherence. These factors collectively shape the competitive landscape and moderate yet steady market growth in South Africa’s diabetes drugs sector.
The South African diabetes drugs market is geographically diverse, with major urban provinces such as Gauteng, Western Cape, and KwaZulu-Natal driving demand due to their advanced healthcare infrastructure and high diabetes prevalence. Rural regions, including parts of Eastern Cape, are experiencing gradual market expansion as government initiatives improve access to essential diabetes medications. Key players in the market include Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, AstraZeneca, and Boehringer Ingelheim, among others. These pharmaceutical giants dominate the industry by offering a wide range of insulin products, oral antidiabetic drugs, and innovative therapies such as GLP-1 receptor agonists and SGLT2 inhibitors. Companies are investing in research and development (R&D) to enhance treatment options and expand their market presence. Additionally, strategic collaborations with healthcare providers and government programs are improving drug availability and affordability, ensuring broader patient access to diabetes treatments across South Africa.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
The South Africa diabetes drugs market was valued at USD 330.45 million in 2023 and is projected to reach USD 353.64 million by 2032, growing at a CAGR of 0.31%.
Rising diabetes prevalence, driven by urbanization, aging populations, and lifestyle changes, is a key market driver.
Advanced drug classes, including GLP-1 receptor agonists and SGLT2 inhibitors, are gaining traction due to their superior efficacy and additional health benefits.
Leading pharmaceutical companies such as Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, and AstraZeneca dominate the market through innovative product offerings and strategic partnerships.
High treatment costs and unequal access to healthcare remain significant challenges, particularly in rural and lower-income communities.
Gauteng and Western Cape lead the market due to advanced healthcare facilities, while rural regions are experiencing gradual growth due to improved accessibility.
Government initiatives, digital health solutions, and increasing adoption of combination therapies are shaping the future of diabetes management in South Africa.
Report Scope
This report segments the South Africa Diabetes Drugs Market as follows:
Market Drivers
Rising Diabetes Prevalence and Aging Population
The increasing prevalence of diabetes in South Africa is a major driver of market growth. A combination of genetic predisposition, urbanization, and lifestyle changes has led to a significant rise in type 2 diabetes cases. For instance, the International Diabetes Federation (IDF) reported that 11.3% of adults in South Africa were living with diabetes as of 2021, with over 4.2 million cases documented. The aging population further contributes to the demand for diabetes drugs, as elderly individuals are more susceptible to the disease and its complications. This demographic shift underscores the need for effective and accessible diabetes treatments, boosting pharmaceutical sales and market expansion.
Government Initiatives and Healthcare Access Expansion
The South African government plays a crucial role in expanding access to diabetes medication through public healthcare policies and national health insurance programs. For instance, the National Department of Health’s Strategic Plan for the Prevention and Control of Non-Communicable Diseases includes initiatives to integrate diabetes management into primary healthcare services, improving early diagnosis and treatment accessibility. Subsidized medication programs and partnerships with pharmaceutical companies further ensure that essential diabetes drugs are available at reduced costs. Additionally, regulatory support for the development and approval of generic alternatives enhances affordability, allowing a larger patient base to benefit from effective diabetes treatments.
Advancements in Diabetes Treatment and Innovation
Technological advancements and pharmaceutical innovations have transformed diabetes management in South Africa. The introduction of newer drug classes, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, offers improved efficacy and fewer side effects compared to traditional treatments. The increasing adoption of combination therapies, which enhance glycemic control while reducing the burden of multiple medications, further drives demand. Moreover, digital health solutions, including mobile apps for glucose monitoring and telemedicine consultations, are becoming more prevalent, providing patients with better disease management tools and driving the market forward.
Growing Awareness and Preventive Healthcare Initiatives
Rising awareness about diabetes and its complications has led to increased demand for early diagnosis and effective treatment options. Public and private sector initiatives focus on educating individuals about the importance of lifestyle modifications, regular screenings, and medication adherence. Non-governmental organizations (NGOs) and healthcare providers actively engage in outreach programs, emphasizing preventive measures and early intervention strategies. As a result, more South Africans are seeking medical attention and adhering to prescribed treatment regimens, ultimately contributing to market growth. Additionally, corporate wellness programs encourage employees to monitor their health, further driving the demand for diabetes drugs.
Market Trends
Increased Adoption of Innovative Drug Therapies
The South African diabetes drugs market is witnessing a shift toward advanced treatment options, driven by the growing adoption of innovative drug classes such as GLP-1 receptor agonists and SGLT2 inhibitors. These therapies offer superior glycemic control, weight management benefits, and reduced cardiovascular risks compared to traditional medications like sulfonylureas and metformin. For instance, the South African Diabetes Advocacy has reported a significant increase in the prescription of GLP-1 receptor agonists, particularly for patients with type 2 diabetes and cardiovascular risks. As healthcare providers recognize the advantages of these newer drugs, their prescription rates continue to rise. However, affordability remains a challenge, leading to increased demand for generic versions and government-subsidized treatment programs.
Rising Demand for Combination Therapies
Combination drug therapies are gaining popularity in South Africa due to their ability to improve treatment adherence and patient outcomes. Fixed-dose combinations that integrate multiple active ingredients into a single pill simplify medication regimens, reducing pill burden and enhancing patient compliance. This trend aligns with healthcare providers’ efforts to optimize diabetes management by addressing multiple disease pathways simultaneously. Pharmaceutical companies are investing in research and development (R&D) to introduce more effective combination therapies tailored to diverse patient needs, further driving market growth.
Expansion of Digital Health and Telemedicine Solutions
The integration of digital health technologies is revolutionizing diabetes management in South Africa. Mobile applications, wearable glucose monitors, and telemedicine platforms are enabling patients to monitor their blood sugar levels and consult healthcare providers remotely. For instance, the “Sisonke Health” telemedicine platform has facilitated remote consultations for diabetes patients in rural areas, improving access to specialized care. These innovations improve disease monitoring, facilitate timely interventions, and reduce the burden on healthcare facilities. The COVID-19 pandemic accelerated the adoption of telemedicine, making remote diabetes care a more permanent fixture in the healthcare landscape. This trend is expected to continue, promoting better patient engagement and medication adherence.
Growing Focus on Preventive Healthcare and Lifestyle Management
Preventive healthcare is becoming a key focus in diabetes management, with increased emphasis on lifestyle interventions such as diet, exercise, and weight management. Public health campaigns, corporate wellness programs, and community-driven initiatives are educating individuals about the importance of early intervention and lifestyle modifications. This trend is influencing pharmaceutical strategies, with companies developing drugs that complement lifestyle-based treatments. Additionally, an increasing number of patients are seeking holistic approaches that combine medication with non-pharmacological interventions, shaping the future of diabetes care in South Africa.
Market Challenges Analysis
Limited Access and Affordability Constraints
One of the biggest challenges in the South African diabetes drugs market is limited access to affordable medication. A significant portion of the population relies on public healthcare facilities, where medication shortages and funding constraints often hinder consistent treatment availability. For instance, the South African Medical Research Council (SAMRC) reported that rural clinics frequently face shortages of essential diabetes medications, leaving patients without consistent access to treatment. While innovative diabetes drugs offer superior efficacy, their high costs make them inaccessible to many patients, particularly those without private health insurance. The dominance of generic drugs helps improve affordability, but concerns about quality and efficacy sometimes limit their widespread acceptance. Additionally, disparities in healthcare infrastructure between urban and rural areas exacerbate access issues, leaving many patients in remote regions with inadequate diabetes management options.
Healthcare System Strain and Treatment Adherence Issues
South Africa’s healthcare system faces increasing pressure due to the rising burden of diabetes and other chronic diseases. Public hospitals and clinics often experience overcrowding, long wait times, and resource limitations, making it difficult for patients to receive timely treatment and follow-up care. This strain contributes to poor treatment adherence, as patients struggle to maintain regular check-ups and medication routines. Furthermore, a lack of diabetes education and awareness leads to delayed diagnoses and improper medication use, reducing treatment effectiveness. Socioeconomic factors, including unemployment and food insecurity, also impact patients’ ability to maintain healthy lifestyles, further complicating diabetes management. Addressing these challenges requires coordinated efforts from the government, healthcare providers, and pharmaceutical companies to improve accessibility, affordability, and patient education.
Market Opportunities
The South African diabetes drugs market presents significant opportunities for growth, driven by increasing investments in healthcare infrastructure and the expansion of universal health coverage initiatives. As the government strengthens its commitment to improving public healthcare, there is potential for enhanced distribution of essential diabetes medications, particularly in underserved rural areas. The rising prevalence of diabetes also creates demand for cost-effective treatment options, providing opportunities for pharmaceutical companies to introduce affordable generic alternatives. Additionally, public-private partnerships can play a crucial role in improving access to innovative therapies, ensuring that a larger patient population benefits from advanced diabetes management solutions.
Technological advancements and the growing adoption of digital health solutions offer further opportunities for market expansion. The integration of telemedicine, wearable glucose monitoring devices, and mobile health applications is transforming diabetes care by enhancing patient engagement and improving treatment adherence. Companies investing in digital health solutions can capitalize on the increasing demand for remote monitoring and personalized diabetes management tools. Furthermore, growing health awareness and preventive care initiatives present opportunities for pharmaceutical firms to collaborate with healthcare providers and wellness programs to promote early intervention and lifestyle-based disease management. These factors position the South African diabetes drugs market for steady growth and innovation in the coming years.
Market Segmentation Analysis:
By Drug Class:
The South African diabetes drugs market is categorized into various drug classes, including insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others. Insulin remains a dominant segment due to its essential role in managing type 1 diabetes and advanced cases of type 2 diabetes. The demand for rapid-acting and long-acting insulin formulations is increasing, driven by the need for better glycemic control and reduced hypoglycemia risks. DPP-4 inhibitors, known for their ability to enhance insulin secretion and lower blood glucose levels without causing significant weight gain, continue to be widely prescribed. The market is also witnessing a rising adoption of GLP-1 receptor agonists and SGLT2 inhibitors, which offer additional cardiovascular and renal benefits. These newer drug classes are gaining popularity among healthcare providers due to their improved patient outcomes and reduced side effects. The “Others” category includes traditional oral antidiabetics and emerging therapies, which continue to play a role in diabetes management, particularly in cost-sensitive patient groups.
By Diabetes Types:
The market is also segmented based on diabetes types, including type 1, type 2, type 3, type 4, and type 5 diabetes. Type 2 diabetes constitutes the largest market share, driven by the increasing prevalence of obesity, sedentary lifestyles, and poor dietary habits. The demand for oral antidiabetic drugs, including DPP-4 inhibitors and SGLT2 inhibitors, is rising as patients seek effective yet convenient treatment options. Type 1 diabetes, though less prevalent, maintains a steady demand for insulin therapies, as insulin remains the primary treatment. Less common forms of diabetes, such as types 3, 4, and 5, represent niche market segments with specialized treatment needs. These categories include conditions related to neurodegenerative diseases, pancreatic disorders, and genetic factors, creating opportunities for targeted research and pharmaceutical innovation. As awareness and diagnosis rates improve, the demand for tailored treatment solutions in these subcategories is expected to grow, further expanding the overall diabetes drugs market in South Africa.
Segments:
Based on Drug Class:
Insulin
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT2 Inhibitors
Others
Based on Diabetes Types:
Type 1
Type 2
Diabetes Type 3
Diabetes Type 4
Diabetes Type 5
Based on Route of Administration:
Oral
Subcutaneous
Intravenous
Route of Administration 4
Route of Administration 5
Based on Technology:
Technology 1
Technology 2
Technology 3
Based on Distribution Channel:
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Distribution Channel 4
Distribution Channel 5
Based on the Geography:
Gauteng
Western Cape
KwaZulu-Natal
Eastern Cape
Regional Analysis
Gauteng
Gauteng holds the largest market share in the South African diabetes drugs market, accounting for approximately 35% of total sales. As the country’s economic hub, Gauteng has the highest concentration of healthcare facilities, private hospitals, and specialized diabetes care centers, which contribute to higher drug consumption. The province’s urban lifestyle and dietary habits have led to an increasing prevalence of type 2 diabetes, driving demand for both insulin and oral antidiabetic medications such as DPP-4 inhibitors and SGLT2 inhibitors. Furthermore, the availability of advanced healthcare infrastructure and a well-established pharmaceutical supply chain ensures consistent access to diabetes medications. Rising awareness initiatives and government-supported healthcare programs in Gauteng further boost market growth, making it the most significant contributor to South Africa’s diabetes drug industry.
Western Cape
Western Cape represents around 25% of the South African diabetes drugs market, supported by its advanced healthcare system and strong presence of research institutions. The province has a high prevalence of diabetes, particularly among aging populations and communities with genetic predispositions to the disease. The demand for innovative treatments, such as GLP-1 receptor agonists and combination therapies, is steadily increasing due to the growing focus on improved patient outcomes. The Western Cape’s well-developed private healthcare sector and efficient distribution networks enhance access to premium diabetes medications, contributing to its significant market share. Additionally, provincial health initiatives that promote early diagnosis and lifestyle management strategies help drive the adoption of diabetes drugs in the region.
KwaZulu-Natal
KwaZulu-Natal holds approximately 20% of the market share, driven by the province’s large and diverse population, including a significant portion of patients relying on public healthcare services. The region has a high burden of diabetes, particularly among low-income groups, which fuels the demand for cost-effective treatments such as generic insulin and oral antidiabetic medications. Government healthcare programs and nonprofit organizations play a crucial role in improving access to essential diabetes drugs, especially in rural and semi-urban areas. While public healthcare facilities experience challenges such as drug shortages and high patient volumes, ongoing efforts to strengthen diabetes care services and expand pharmaceutical distribution channels are expected to support steady market growth in KwaZulu-Natal.
Eastern Cape
Eastern Cape accounts for 15% of the South African diabetes drugs market, with growth driven by increasing awareness and improved healthcare accessibility. The province has historically faced challenges related to healthcare infrastructure and medication availability, particularly in rural communities. However, recent investments in healthcare services and expanded distribution of diabetes drugs through government programs are improving patient access to essential medications. The demand for insulin and oral antidiabetics is steadily rising as more individuals seek medical intervention for diabetes management. Additionally, community-based health initiatives and collaborations between public and private sectors are helping to bridge healthcare gaps, creating further opportunities for market expansion in Eastern Cape.
Key Player Analysis
Novo Nordisk A/S
Sanofi
Merck & Co., Inc.
Eli Lilly and Company
AstraZeneca
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim International GmbH
Novartis AG
Johnson & Johnson Services, Inc.
Bayer AG
Competitive Analysis
The South African diabetes drugs market is highly competitive, with leading pharmaceutical companies driving innovation and market expansion. Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, AstraZeneca, Boehringer Ingelheim, Takeda Pharmaceutical, Novartis, Johnson & Johnson, and Bayer are among the dominant players shaping the industry. These companies focus on research and development (R&D) to introduce advanced diabetes treatments, including GLP-1 receptor agonists, SGLT2 inhibitors, and combination therapies that improve glycemic control and reduce complications. Leading players invest heavily in research and development (R&D) to introduce advanced diabetes treatments, including novel insulin formulations, GLP-1 receptor agonists, and SGLT2 inhibitors, which offer superior glycemic control and additional health benefits. The adoption of combination therapies is also rising, as they improve treatment adherence and simplify diabetes management. Market competition is further fueled by strategic collaborations with healthcare providers, government programs, and digital health initiatives aimed at enhancing patient outcomes. Companies are expanding their product portfolios to cater to both premium and cost-sensitive segments, ensuring a balance between innovative and generic drug offerings. Price pressures and healthcare accessibility challenges remain key restraints, but efforts to improve distribution networks and expand telemedicine services are helping drive market growth and ensure broader patient coverage.
Recent Developments
In March 2025, Novo Nordisk signed a deal worth up to $2 billion for the rights to UBT251, a new obesity and diabetes drug developed by United BioTechnology. The drug combines GLP-1, GIP, and glucagon to manage blood sugar and reduce hunger.
In February 2025, Sanofi received FDA approval for MERILOG, the first rapid-acting insulin aspart biosimilar, to improve glycemic control in adults and pediatric patients with diabetes.
In December 2024, JD Health began offering Merck’s GLUCOPHAGE XR (Reduce Mass) online in China, enhancing access to metformin hydrochloride extended-release tablets for type 2 diabetes patients.
In December 2024, Torrent Pharma acquired three diabetes brands from Boehringer Ingelheim, including those with Empagliflozin, to strengthen its anti-diabetes portfolio
In November 2024, AstraZeneca presented promising early data for its obesity pipeline, including AZD5004, an oral GLP-1 receptor blocker, at ObesityWeek 2024.
Market Concentration & Characteristics
The South African diabetes drugs market is moderately concentrated, with a few dominant multinational pharmaceutical companies controlling a significant portion of sales. These companies leverage extensive research and development (R&D) capabilities, strong distribution networks, and well-established brand reputations to maintain their competitive edge. The market is characterized by a mix of innovative patented drugs and cost-effective generic alternatives, catering to diverse patient needs. Insulin and oral antidiabetic drugs dominate the treatment landscape, with growing adoption of advanced drug classes such as GLP-1 receptor agonists and SGLT2 inhibitors. Market characteristics include increasing government involvement in diabetes management, a rising focus on preventive care, and expanding digital health solutions to improve patient adherence. While affordability and accessibility challenges persist, ongoing investments in healthcare infrastructure and pharmaceutical innovation continue to shape market dynamics, driving both competition and growth in the sector.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The research report offers an in-depth analysis based on Drug Class,Diabetes Types, Route of Administration, Technology, Distribution Channeland Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The South African diabetes drugs market is expected to grow steadily, driven by rising diabetes prevalence and increased healthcare awareness.
Advanced drug classes, including GLP-1 receptor agonists and SGLT2 inhibitors, will see higher adoption due to their improved efficacy and additional health benefits.
Insulin demand will continue to rise, particularly for long-acting and combination formulations to enhance glycemic control.
Government initiatives and healthcare policies will focus on expanding access to affordable diabetes treatments in underserved regions.
Digital health solutions, including telemedicine and wearable glucose monitoring devices, will improve patient engagement and treatment adherence.
Pharmaceutical companies will invest more in research and development to introduce innovative therapies tailored to local market needs.
The expansion of generic alternatives will help improve affordability and increase market penetration in low-income populations.
Public-private partnerships will strengthen healthcare infrastructure and enhance distribution channels for diabetes medications.
Preventive healthcare strategies and lifestyle interventions will gain more emphasis to reduce the long-term burden of diabetes.
Market competition will intensify as multinational and local pharmaceutical companies expand their presence and introduce cost-effective treatment solutions.
CHAPTER NO. 1 : INTRODUCTION 19
1.1.1. Report Description 19 Purpose of the Report 19 USP & Key Offerings 19
1.1.2. Key Benefits for Stakeholders 19
1.1.3. Target Audience 20
1.1.4. Report Scope 20 CHAPTER NO. 2 : EXECUTIVE SUMMARY 21
2.1. DIABETES DRUGS Market Snapshot 21
2.1.1. South Africa DIABETES DRUGS Market, 2018 – 2032 (USD Million) 22 CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23
3.1. Russia-Ukraine and Israel-Palestine War Impacts 23 CHAPTER NO. 4 : DIABETES DRUGS MARKET – INDUSTRY ANALYSIS 24
4.1. Introduction 24
4.2. Market Drivers 25
4.2.1. Driving Factor 1 Analysis 25
4.2.2. Driving Factor 2 Analysis 26
4.3. Market Restraints 27
4.3.1. Restraining Factor Analysis 27
4.4. Market Opportunities 28
4.4.1. Market Opportunity Analysis 28
4.5. Porter’s Five Forces Analysis 29
4.6. Value Chain Analysis 30
4.7. Buying Criteria 31 CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32
5.1. Import Analysis by South Africa 32
5.1.1. South Africa DIABETES DRUGS Market Import Volume/Revenue, By South Africa, 2018 – 2023 32
5.2. Export Analysis by South Africa 33
5.2.1. South Africa DIABETES DRUGS Market Export Volume/Revenue, By South Africa, 2018 – 2023 33 CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34
6.1. Demand Analysis by South Africa 34
6.1.1. South Africa DIABETES DRUGS Market Demand Volume/Revenue, By South Africa, 2018 – 2023 34
6.2. Supply Analysis by South Africa 35
6.2.1. South Africa DIABETES DRUGS Market Supply Volume/Revenue, By South Africa, 2018 – 2023 35 CHAPTER NO. 7 : PRODUCTION ANALYSIS 36
7.1. Production Analysis by South Africa 36
7.1.1. South Africa DIABETES DRUGS Market Production Volume/Revenue, By South Africa, 2018 – 2023 36 CHAPTER NO. 8 : PRICE ANALYSIS 37
8.1. Price Analysis by Drug Class 37
8.1.1. South Africa DIABETES DRUGS Market Price, By Drug Class, 2018 – 2023 37
8.1.2. South Africa Drug Class Market Price, By Drug Class, 2018 – 2023 37 CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38
9.1. Key Raw Materials and Suppliers 38
9.2. Key Raw Materials Price Trend 38 CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39
10.1. Manufacturing Cost Analysis 39
10.2. Manufacturing Process 39 CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40
11.1. Company Market Share Analysis – 2023 40
11.1.1. South Africa DIABETES DRUGS Market: Company Market Share, by Volume, 2023 40
11.1.2. South Africa DIABETES DRUGS Market: Company Market Share, by Revenue, 2023 41
11.1.3. South Africa DIABETES DRUGS Market: Top 6 Company Market Share, by Revenue, 2023 41
11.1.4. South Africa DIABETES DRUGS Market: Top 3 Company Market Share, by Revenue, 2023 42
11.2. South Africa DIABETES DRUGS Market Company Volume Market Share, 2023 43
11.3. South Africa DIABETES DRUGS Market Company Revenue Market Share, 2023 44
11.4. Company Assessment Metrics, 2023 45
11.4.1. Stars 45
11.4.2. Emerging Leaders 45
11.4.3. Pervasive Players 45
11.4.4. Participants 45
11.5. Start-ups /SMEs Assessment Metrics, 2023 45
11.5.1. Progressive Companies 45
11.5.2. Responsive Companies 45
11.5.3. Dynamic Companies 45
11.5.4. Starting Blocks 45
11.6. Strategic Developments 46
11.6.1. Acquisitions & Mergers 46 New Product Launch 46 South Africa Expansion 46
11.7. Key Players Product Matrix 47 CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48
12.1. PESTEL 48
12.1.1. Political Factors 48
12.1.2. Economic Factors 48
12.1.3. Social Factors 48
12.1.4. Technological Factors 48
12.1.5. Environmental Factors 48
12.1.6. Legal Factors 48
12.2. Adjacent Market Analysis 48 CHAPTER NO. 13 : DIABETES DRUGS MARKET – BY DRUG CLASS SEGMENT ANALYSIS 49
13.1. DIABETES DRUGS Market Overview, by Drug Class Segment 49
13.1.1. DIABETES DRUGS Market Revenue Share, By Drug Class, 2023 & 2032 50
13.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Drug Class 51
13.1.3. Incremental Revenue Growth Opportunity, by Drug Class, 2024 – 2032 51
13.1.4. DIABETES DRUGS Market Revenue, By Drug Class, 2018, 2023, 2027 & 2032 52
13.2. Insulin 53
13.3. Dpp-4 Inhibitors 54
13.4. GLP-1 Receptor Agonists 55
13.5. SGLT2 Inhibitors 56
13.6. Others 57 CHAPTER NO. 14 : DIABETES DRUGS MARKET – BY DIABETES TYPES SEGMENT ANALYSIS 58
14.1. DIABETES DRUGS Market Overview, by Diabetes Types Segment 58
14.1.1. DIABETES DRUGS Market Revenue Share, By Diabetes Types, 2023 & 2032 59
14.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Diabetes Types 60
14.1.3. Incremental Revenue Growth Opportunity, by Diabetes Types, 2024 – 2032 60
14.1.4. DIABETES DRUGS Market Revenue, By Diabetes Types, 2018, 2023, 2027 & 2032 61
14.2. Type 1 62
14.3. Type 2 63
14.4. Diabetes Types 3 64
14.5. Diabetes Types 4 65
14.6. Diabetes Types 5 66 CHAPTER NO. 15 : DIABETES DRUGS MARKET – BY ROUTE OF ADMINISTRATION SEGMENT ANALYSIS 67
15.1. DIABETES DRUGS Market Overview, by Route Of Administration Segment 67
15.1.1. DIABETES DRUGS Market Revenue Share, By Route Of Administration , 2023 & 2032 68
15.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Route Of Administration 69
15.1.3. Incremental Revenue Growth Opportunity, by Route Of Administration , 2024 – 2032 69
15.1.4. DIABETES DRUGS Market Revenue, By Route Of Administration , 2018, 2023, 2027 & 2032 70
15.2. Oral 71
15.3. Subcutaneous 72
15.4. Intravenous 73
15.5. Route Of Administration 4 74
15.6. Route Of Administration 5 75 CHAPTER NO. 16 : DIABETES DRUGS MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76
16.1. DIABETES DRUGS Market Overview, by Technology Segment 76
16.1.1. DIABETES DRUGS Market Revenue Share, By Technology, 2023 & 2032 77
16.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Technology 78
16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78
16.1.4. DIABETES DRUGS Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79
16.2. Technology 1 80
16.3. Technology 2 81
16.4. Technology 3 82 CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83
17.1. DIABETES DRUGS Market Overview, by Distribution Channel Segment 83
17.1.1. DIABETES DRUGS Market Revenue Share, By Distribution Channel, 2023 & 2032 84
17.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Distribution Channel 85
17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85
17.1.4. DIABETES DRUGS Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86
17.2. Online Pharmacies 87
17.3. Hospital Pharmacies 88
17.4. Retail Pharmacies 89
17.5. Distribution Channel 4 90
17.6. Distribution Channel 5 91 CHAPTER NO. 18 : DIABETES DRUGS MARKET – SOUTH AFRICA ANALYSIS 92
18.1. Drug Class 92
18.1.1. South Africa DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 (USD Million) 92
18.2. South Africa DIABETES DRUGS Market Revenue, By Drug Class, 2024 – 2032 (USD Million) 92
18.3. Diabetes Types 93
18.3.1. South Africa DIABETES DRUGS Market Revenue, By Diabetes Types, 2018 – 2023 (USD Million) 93
18.3.2. South Africa DIABETES DRUGS Market Revenue, By Diabetes Types, 2024 – 2032 (USD Million) 93
18.4. Route Of Administration 94
18.4.1. South Africa DIABETES DRUGS Market Revenue, By Route Of Administration , 2018 – 2023 (USD Million) 94
18.4.2. South Africa DIABETES DRUGS Market Revenue, By Route Of Administration , 2024 – 2032 (USD Million) 94
18.5. Technology 95
18.5.1. South Africa DIABETES DRUGS Market Revenue, By Technology, 2018 – 2023 (USD Million) 95
18.5.2. South Africa DIABETES DRUGS Market Revenue, By Technology, 2024 – 2032 (USD Million) 95
18.6. Distribution Channel 96
18.6.1. South Africa DIABETES DRUGS Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96
18.6.2. South Africa DIABETES DRUGS Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96 CHAPTER NO. 19 : COMPANY PROFILES 97
19.1. Novo Nordisk A/S 97
19.1.1. Company Overview 97
19.1.2. Product Portfolio 97
19.1.3. Swot Analysis 97
19.1.4. Business Strategy 98
19.1.5. Financial Overview 98
19.1.6. Sanofi 99
19.1.7. Merck & Co., Inc 99
19.1.8. Eli Lilly and Company 99
19.1.9. AstraZeneca 99
19.1.10. Takeda Pharmaceutical Company Limited 99
19.1.11. Boehringer Ingelheim International GmbH 99
19.1.12. Novartis AG 99
19.1.13. Johnson & Johnson Services, Inc. 99
19.1.14. Bayer AG 99
19.1.15. Company 11 99
19.1.16. Company 12 99
19.1.17. Company 13 99
19.1.18. Company 14 99 CHAPTER NO. 20 : RESEARCH METHODOLOGY 100
20.1. Research Methodology 100
20.1.1. Phase I – Secondary Research 101
20.1.2. Phase II – Data Modeling 101 Company Share Analysis Model 102 Revenue Based Modeling 102
20.1.3. Phase III – Primary Research 103
20.1.4. Research Limitations 104 Assumptions 104 List of Figures
FIG NO. 1. South Africa DIABETES DRUGS Market Revenue, 2018 – 2032 (USD Million) 22
FIG NO. 2. Porter’s Five Forces Analysis for South Africa DIABETES DRUGS Market 29
FIG NO. 3. Value Chain Analysis for South Africa DIABETES DRUGS Market 30
FIG NO. 4. South Africa DIABETES DRUGS Market Import Volume/Revenue, By South Africa, 2018 – 2023 32
FIG NO. 5. South Africa DIABETES DRUGS Market Export Volume/Revenue, By South Africa, 2018 – 2023 33
FIG NO. 6. South Africa DIABETES DRUGS Market Demand Volume/Revenue, By South Africa, 2018 – 2023 34
FIG NO. 7. South Africa DIABETES DRUGS Market Supply Volume/Revenue, By South Africa, 2018 – 2023 35
FIG NO. 8. South Africa DIABETES DRUGS Market Production Volume/Revenue, By South Africa, 2018 – 2023 36
FIG NO. 9. South Africa DIABETES DRUGS Market Price, By Drug Class, 2018 – 2023 37
FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38
FIG NO. 11. Manufacturing Cost Analysis 39
FIG NO. 12. Manufacturing Process 39
FIG NO. 13. Company Share Analysis, 2023 40
FIG NO. 14. Company Share Analysis, 2023 41
FIG NO. 15. Company Share Analysis, 2023 41
FIG NO. 16. Company Share Analysis, 2023 42
FIG NO. 17. DIABETES DRUGS Market – Company Volume Market Share, 2023 43
FIG NO. 18. DIABETES DRUGS Market – Company Revenue Market Share, 2023 44
FIG NO. 19. DIABETES DRUGS Market Revenue Share, By Drug Class, 2023 & 2032 50
FIG NO. 20. Market Attractiveness Analysis, By Drug Class 51
FIG NO. 21. Incremental Revenue Growth Opportunity by Drug Class, 2024 – 2032 51
FIG NO. 22. DIABETES DRUGS Market Revenue, By Drug Class, 2018, 2023, 2027 & 2032 52
FIG NO. 23. South Africa DIABETES DRUGS Market for Insulin, Revenue (USD Million) 2018 – 2032 53
FIG NO. 24. South Africa DIABETES DRUGS Market for Dpp-4 Inhibitors, Revenue (USD Million) 2018 – 2032 54
FIG NO. 25. South Africa DIABETES DRUGS Market for GLP-1 Receptor Agonists, Revenue (USD Million) 2018 – 2032 55
FIG NO. 26. South Africa DIABETES DRUGS Market for SGLT2 Inhibitors, Revenue (USD Million) 2018 – 2032 56
FIG NO. 27. South Africa DIABETES DRUGS Market for Others, Revenue (USD Million) 2018 – 2032 57
FIG NO. 28. DIABETES DRUGS Market Revenue Share, By Diabetes Types, 2023 & 2032 59
FIG NO. 29. Market Attractiveness Analysis, By Diabetes Types 60
FIG NO. 30. Incremental Revenue Growth Opportunity by Diabetes Types, 2024 – 2032 60
FIG NO. 31. DIABETES DRUGS Market Revenue, By Diabetes Types, 2018, 2023, 2027 & 2032 61
FIG NO. 32. South Africa DIABETES DRUGS Market for Type 1, Revenue (USD Million) 2018 – 2032 62
FIG NO. 33. South Africa DIABETES DRUGS Market for Type 2, Revenue (USD Million) 2018 – 2032 63
FIG NO. 34. South Africa DIABETES DRUGS Market for Diabetes Types 3, Revenue (USD Million) 2018 – 2032 64
FIG NO. 35. South Africa DIABETES DRUGS Market for Diabetes Types 4, Revenue (USD Million) 2018 – 2032 65
FIG NO. 36. South Africa DIABETES DRUGS Market for Diabetes Types 5, Revenue (USD Million) 2018 – 2032 66
FIG NO. 37. DIABETES DRUGS Market Revenue Share, By Route Of Administration , 2023 & 2032 68
FIG NO. 38. Market Attractiveness Analysis, By Route Of Administration 69
FIG NO. 39. Incremental Revenue Growth Opportunity by Route Of Administration , 2024 – 2032 69
FIG NO. 40. DIABETES DRUGS Market Revenue, By Route Of Administration , 2018, 2023, 2027 & 2032 70
FIG NO. 41. South Africa DIABETES DRUGS Market for Oral, Revenue (USD Million) 2018 – 2032 71
FIG NO. 42. South Africa DIABETES DRUGS Market for Subcutaneous, Revenue (USD Million) 2018 – 2032 72
FIG NO. 43. South Africa DIABETES DRUGS Market for Intravenous, Revenue (USD Million) 2018 – 2032 73
FIG NO. 44. South Africa DIABETES DRUGS Market for Route Of Administration 4, Revenue (USD Million) 2018 – 2032 74
FIG NO. 45. South Africa DIABETES DRUGS Market for Route Of Administration 5, Revenue (USD Million) 2018 – 2032 75
FIG NO. 46. DIABETES DRUGS Market Revenue Share, By Technology, 2023 & 2032 77
FIG NO. 47. Market Attractiveness Analysis, By Technology 78
FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78
FIG NO. 49. DIABETES DRUGS Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79
FIG NO. 50. South Africa DIABETES DRUGS Market for Technology 1, Revenue (USD Million) 2018 – 2032 80
FIG NO. 51. South Africa DIABETES DRUGS Market for Technology 2, Revenue (USD Million) 2018 – 2032 81
FIG NO. 52. South Africa DIABETES DRUGS Market for Technology 3, Revenue (USD Million) 2018 – 2032 82
FIG NO. 53. DIABETES DRUGS Market Revenue Share, By Distribution Channel, 2023 & 2032 84
FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85
FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85
FIG NO. 56. DIABETES DRUGS Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86
FIG NO. 57. South Africa DIABETES DRUGS Market for Online Pharmacies, Revenue (USD Million) 2018 – 2032 87
FIG NO. 58. South Africa DIABETES DRUGS Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 88
FIG NO. 59. South Africa DIABETES DRUGS Market for Retail Pharmacies, Revenue (USD Million) 2018 – 2032 89
FIG NO. 60. South Africa DIABETES DRUGS Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90
FIG NO. 61. South Africa DIABETES DRUGS Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91
FIG NO. 62. Research Methodology – Detailed View 100
FIG NO. 63. Research Methodology 101
List of Tables
TABLE NO. 1. : South Africa DIABETES DRUGS Market: Snapshot 18
TABLE NO. 2. : Drivers for the DIABETES DRUGS Market: Impact Analysis 22
TABLE NO. 3. : Restraints for the DIABETES DRUGS Market: Impact Analysis 24
TABLE NO. 4. : South Africa DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 34
TABLE NO. 5. : Key Raw Materials & Suppliers 35
TABLE NO. 6. : South Africa DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 (USD Million) 89
TABLE NO. 7. : South Africa DIABETES DRUGS Market Revenue, By Drug Class, 2024 – 2032 (USD Million) 89
TABLE NO. 8. : South Africa DIABETES DRUGS Market Revenue, By Diabetes Types, 2018 – 2023 (USD Million) 90
TABLE NO. 9. : South Africa DIABETES DRUGS Market Revenue, By Diabetes Types, 2024 – 2032 (USD Million) 90
TABLE NO. 10. : South Africa DIABETES DRUGS Market Revenue, By Route Of Administration , 2018 – 2023 (USD Million) 91
TABLE NO. 11. : South Africa DIABETES DRUGS Market Revenue, By Route Of Administration , 2024 – 2032 (USD Million) 91
TABLE NO. 12. : South Africa DIABETES DRUGS Market Revenue, By Technology, 2018 – 2023 (USD Million) 92
TABLE NO. 13. : South Africa DIABETES DRUGS Market Revenue, By Technology, 2024 – 2032 (USD Million) 92
TABLE NO. 14. : South Africa DIABETES DRUGS Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93
TABLE NO. 15. : South Africa DIABETES DRUGS Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93
Frequently Asked Questions:
What is the current size of the South Africa Diabetes Drugs Market?
The South Africa diabetes drugs market was valued at USD 330.45 million in 2023 and is projected to reach USD 353.64 million by 2032, growing at a compound annual growth rate (CAGR) of 0.31% during the forecast period (2023-2032)..
What factors are driving the growth of the South Africa Diabetes Drugs Market?
The market is driven by rising diabetes prevalence, an aging population, and increasing urbanization, which contribute to lifestyle-related risk factors such as obesity and sedentary behavior.
What are the key segments within the South Africa Diabetes Drugs Market?
The market is segmented by drug class into insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and others. It is also categorized by diabetes type, including Type 1, Type 2, Type 3, Type 4, and Type 5. Based on route of administration, the market is divided into oral, subcutaneous, and intravenous therapies. The distribution channel segment includes online pharmacies, hospital pharmacies, and retail pharmacies.
What are some challenges faced by the South Africa Diabetes Drugs Market?
The market faces challenges such as high treatment costs, unequal access to healthcare, and economic constraints that limit access to advanced diabetes therapies. Dependence on public healthcare facilities, medication shortages, and affordability concerns further hinder market expansion.
Who are the major players in the South Africa Diabetes Drugs Market?
Leading pharmaceutical companies in the market include Novo Nordisk, Sanofi, Merck & Co., Eli Lilly, AstraZeneca, Takeda Pharmaceutical, Boehringer Ingelheim, Novartis, Johnson & Johnson, and Bayer.
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$2699
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$3699
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.
